Recently, HeartEpoch, a polymer heart valve R&D and production platform enterprise, announced that it has received tens of millions of yuan in angel round funding, with the investor being the Pudong Technology Investment Angel Fund under the Pudong Venture Capital Group.HeartEpoch was registered and established in Zhangjiang, Shanghai in 2022. It focuses on the innovation and development of heart valve products, aiming to break through the treatment bottleneck of valvular heart diseases and provide safer, more efficient, and more economical medical solutions for patients with valvular diseases worldwide.The company has successively won the first prize in the 2024 China Medical Device Innovation Competition, the third prize in the third "Innovate and Lead Pudong" competition, and the honor of being a national-level technology-based small and medium-sized enterprise. The founding team has many years of R&D experience in the heart valve field from leading medical device companies both in China and abroad, and possesses strong technical development and productization capabilities.HeartEpoch, adhering to the concept of combining technological innovation with clinical needs, has launched a groundbreaking polymer valve product. This product effectively integrates the advantages of mechanical and biological valves, offering benefits such as a long service life, zero calcification, low thrombogenicity, and high biocompatibility, while significantly reducing treatment costs. This innovative product is also expected to address the issue of Chinese valve companies' reliance on imported leaflet materials, further promoting the development of China's medical device industry.
